Bone Metastasis Market Forecasts to 2028 – Global Analysis By Product (Targeted Therapy Agents, Bone Building Medications, Pain Relievers and Other Products), By Diagnosis (Blood Test, Biopsy, Imaging and Other Diagnosis), By Treatment, By Type, By Origin

Bone Metastasis Market Forecasts to 2028 – Global Analysis By Product (Targeted Therapy Agents, Bone Building Medications, Pain Relievers and Other Products), By Diagnosis (Blood Test, Biopsy, Imaging and Other Diagnosis), By Treatment, By Type, By Origin, By End User and By Geography

According to Stratistics MRC, the Global Bone Metastasis Market is accounted for $19.7 billion in 2022 and is expected to reach $37.4 billion by 2028 growing at a CAGR of 11.3% during the forecast period. In basic terms, bone metastasis (also known as bone mets) happens when cancer cells fragment from a primary tumor located anywhere else in the body, move through the bloodstream or lymph system to a portion of the bone, and then develop into metastatic cancer cells. A primary bone tumor, which typically begins in the bone, is different from this. When these cancer cells invade the bone, they release chemicals that either activate osteoblasts or osteoclasts. Osteoclasts result in bone disintegration without new bone formation, which weakens the bones.

According to Cancer Research U.K, in males, prostate cancer is the most common cancer, with around 47,200 new cases each year.

Market Dynamics

Driver

High prevalence of cancer

The primary reasons driving the global market for treatments for bone metastasis are the high prevalence and rising incidence rates of the causes of bone metastasis, particularly breast cancer and prostate cancer. Each year, more than 2.1 million women undergo a breast cancer diagnosis, according to the World Health Organization (WHO). Globocan estimates that 1,276,106 new cases of prostate cancer were diagnosed worldwide in 2018. The increasing prevalence and rising incidence rates of bone metastasis around the world are hence one of the key factors anticipated to drive the market for the treatment of bone metastasis during the projected timeframe.

Restraint

High treatment cost

A multidisciplinary approach is necessary for the management of patients with metastatic bone disease to ensure adequate diagnostic evaluation and therapy planning. To maximize treatment outcomes, a multi-modal treatment strategy that combines medical therapy, radiation, and surgery would be beneficial. Surgery for metastatic disease aims to reduce pain, regain functional independence, and enhance patients' overall quality of life. However, complications and high treatment costs may limit market growth.

Opportunity

Technological advancements

Bone metastases, which frequently cause intense pain, pathological fractures, and nerve damage in cancer patients, have a major negative influence on quality of life and life expectancy. Even though current therapeutic options are often just palliative and not curative, surgery is still the gold standard for treating bone metastases. The primary objective of surgical intervention is to replace the damaged bone with a bioimplant, which can be made from materials derived from diverse sources and fabricated utilizing a range of techniques that have evolved through time in accordance with clinical requirements.

Threat

Untapped emerging markets and lack of healthcare services

The untapped emerging markets, however, hinder the market from expanding. Within the projected period, it is also anticipated that the lack of healthcare services in low-income nations will restrain market expansion. The Food and Drug Administration's (FDA) slow drug approval process for cancer treatments is another significant issue limiting the growth of the bone metastasis market. Additionally, the market revenue growth of bone metastasis is hampered by the lack of diagnostic methods for the disorder.

Covid-19 Impact

The global COVID outbreak has placed cancer patients in considerable jeopardy. Leading hospitals and research facilities advise cancer patients to stay at home until COVID infections disappear due to concerns about their poor immunity levels. The postponement of operations, radiation treatments, and chemotherapy sessions has disrupted the treatment plans of several cancer patients worldwide. Cancer patients may have lowered immunity, making them more vulnerable to contracting the virus. And if it happens, the patient will pass away very quickly. Doctors are therefore taking all necessary measures to keep kids safe, at least from COVID.

The osteolytic bone metastasis segment is expected to be the largest during the forecast period

Osteolytic Bone Metastasis is witnessed to hold the dominant share over the forecast period. The most common type of bone metastasis in cancer patients is osteolytic metastasis. Although a localized response to bone growth is also present, the primary lesion is lytic and destructive. Osteolytic metastases can form in solid tumors such as breast cancer, prostate cancer, thyroid cancer, lung cancer, and renal cancer.

The biopsy segment is expected to have the highest CAGR during the forecast period

Biopsy segment is anticipated to have lucrative growth over the projected period. In order to detect the presence of cancer or other abnormal cells, bone samples are taken during surgery or using a particular biopsy needle. A bone biopsy involves the outer layers of the bone, as opposed to a bone marrow biopsy, which involves the interior portion of the bone. These elements are augmenting the segments growth.

Region with largest share

North America is predicted to hold the largest share throughout the domination period due to the region's expanding breast cancer prevalence and the existence of a highly developed healthcare industry. However, the region has witnessed an increase in cancer cases as a result of the consumption of highly processed foods and sugary beverages, obesity, Type 2 diabetes, sedentary lifestyles, and rising alcohol consumption. It is projected that rising market demand will result from expanding research on cancer stem cells.

Region with highest CAGR

Asia-Pacific region is projected to have a lucrative CAGR throughout the anticipated period due to a booming healthcare industry and increase in the number of patients with bone metastases, government initiatives to raise awareness, and an increase in demand for the therapy. Additionally, the existence of a significant population in the area is one of the major factors projected to positively influence the growth of the bone metastasis market. Moreover, china is accounted to be responsible for 50% of all cancer cases in the Asia-Pacific region.

Key players in the market

Some of the key players in Bone Metastasis market include Amgen Inc. , Bayer, BeiGene, Centus Biotherapeutics Ltd, Eli Lilly and Company, General Electric, Koninklijke Philips N.V., Medtronic, Merck & Co., Inc., Novartis Ag, Novicure Biotechnology, Oncobone Ltd, Pfizer Inc, Pharmalucence Inc, Q Biomed Inc., Siemens Ag And Toshiba Corporation.

Key Developments

In March 2022, FDA approved Novartis Pluvicto as the first targeted radioligand therapy for the management of metastatic castration-resistant prostate cancer.

In June 2021, Bayer announced that it had reached a deal to purchase PSMA Therapeutics Inc. and Noria Therapeutics Inc. The acquisition increases the scope of Bayer's current oncology portfolio.

Products Covered
• Targeted Therapy Agents
• Bone Building Medications
• Pain Relievers
• Other Products

Diagnosis Covered
• Blood Test
• Biopsy
• Imaging
• Other Diagnosis

Treatments Covered
• Medical Therapies
• Surgery
• Medication

Types Covered
• Mixed Bone Metastasis
• Osteoblastic Bone Metastasis
• Osteolytic Bone Metastasis
• Other Types

Origins Covered
• Prostate
• Kidney
• Thyroid
• Lung
• Breast

End Users Covered
• Ambulatory Surgical Centers
• Pharmacies
• Diagnostic Centers
• Hospital & Clinics
• Other End Users

Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities,Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements